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Resolution-phase macrophage population orchestrates active dampening of the inflam-
mation by secreting anti-inflammatory and proresolving products including interleukin 
(IL)-10 and lipid mediators (LMs). We investigated the effects of both human bone 
marrow-derived mesenchymal stromal cells (MSCs) and MSC-derived extracellular 
vesicles (MSC-EVs) on mature human regulatory macrophages (Mregs). The cytokines 
and LMs were determined from cell culture media of Mregs cultivated with MSCs and 
MSC-EVs. In addition, the alterations in the expression of cell surface markers and the 
phagocytic ability of Mregs were investigated. Our novel findings indicate that both MSC 
coculture and MSC-EVs downregulated the production of IL-23 and IL-22 enhancing 
the anti-inflammatory phenotype of Mregs and amplifying proresolving properties. The 
levels of prostaglandin E2 (PGE2) were substantially upregulated in MSC coculture media, 
which may endorse proresolving LM class switching. In addition, our results manifest, 
for the first time, that MSC-EVs mediate the Mreg phenotype change via PGE2. These 
data suggest that both human MSC and MSC-EVs may potentiate tolerance-promoting 
proresolving phenotype of human Mregs.
Keywords: regulatory macrophages, mesenchymal stromal cells, extracellular vesicles, interleukin-23, 
prostaglandin e2, resolution
inTrODUcTiOn
Inflammation is a crucial component of host tissue response, and controlling its initiation, progress, 
resolution, and post-resolution phases is essential for recovering tissue homeostasis. The overlapping 
stages of the cascade are moderated by macrophages, which are highly versatile and dynamic cells 
responding to various microenvironmental stimuli (1, 2). Macrophages exist as a heterogeneous 
population and display a spectrum of phenotypes both in vivo and in vitro depending on the provided 
signals. Conventional terms for two paradigmatic populations include classically activated “host 
defense” M1 and alternatively activated “wound-healing” M2. Additional concepts of “regulatory 
macrophages” or “Mregs” have emerged within the last decade (3–6).
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At the resolution phase, the macrophage population shifts 
toward a resolving phenotype (7). These immune regulatory 
macrophages (Mregs) are characterized by immunosuppressive 
properties, such as high production of interleukin (IL)-10 and 
transforming growth factor (TGF)-β, and a downregulated 
production of pro-inflammatory IL-12 (3, 8, 9). The induction of 
Mreg populations may follow both innate and adaptive immune 
responses and arise from various stimuli including glucocorti-
coids, immune complexes, prostaglandins (PGs), IL-10, and 
apoptotic cells, combined with a second stimulus, such as a 
toll-like receptor ligand (3, 9–12). In recent years, Hutchinson 
and coworkers have established an experimental method for the 
preparation of ex vivo-manipulated regulatory macrophages. 
These cells suppress mitogen-stimulated T-cell proliferation 
in vitro and have been used as a promising immunosuppressive 
agent in early-phase clinical trials in renal transplantations (6, 13).
In addition to anti-inflammatory cytokines, lipid mediators 
(LMs) play an important role in the resolution phase. The resolu-
tion is initiated with LM class switching, in which PGs act as a 
cue for the conversion of pro-inflammatory to proresolving LM 
production. PGE2 and PGD2 induce neutrophils to produce fewer 
pro-inflammatory 5-lipoxygenase (5-LOX)-derived LMs, such as 
leukotrienes, and increase the production of 15-LOX products, 
such as lipoxins (LXs), through cyclic adenosine monophosphate 
induction and regulation of the gene transcription of 15-LOX 
(14). Proresolving LMs, termed specialized proresolving media-
tors (SPMs), reduce inflammation by decreasing neutrophil 
recruitment and increasing macrophage-mediated phagocytosis 
and efferocytosis (15). Macrophages are known to produce SPMs 
such as LXs, resolvins (Rvs), protectins, and maresins (16).
Mesenchymal stromal cells (MSCs) are multipotent adult stem 
cells that have been widely used in experimental cell therapy 
due to their immunosuppressive and anti-inflammatory proper-
ties (17). Key players in MSC immunomodulation include the 
tryptophan-degrading enzyme indoleamine 2,3-dioxygenase, 
adenosine-producing CD73, and PGE2 (18–22). MSCs are able 
to polarize macrophages toward a more anti-inflammatory phe-
notype in a PGE2-mediated manner (23–25). MSCs may improve 
the phagocytosis of macrophages by transporting mitochondria to 
macrophages via tunneling nanotube-like structures (26). MSCs 
have also been reported to produce SPMs in a murine model (27), 
but the evidence on SPM biosynthesis in human MSCs is limited, 
and only the production of an important proresolving mediator 
LXA4 has been described (28). In addition to secreted soluble 
molecules, paracrine activity via extracellular vesicles (EVs) is 
an important function of MSCs. MSC-derived EVs (MSC-EVs) 
mediate the immunosuppressive effect of MSCs (29, 30) and may 
also elicit a similar therapeutic response as the cells themselves 
(31–33). Lo Sicco et al. recently reported that human MSC-EVs 
are able to trigger polarization from the M1 to M2 phenotype in 
a murine model both in vitro and in vivo (34).
Mregs are considered an important proresolving cell popula-
tion during the later stages of the immune response. Despite this 
prominent role, the cooperation between Mregs and other well-
known immunomodulatory agents, such as MSCs, is sparsely 
studied. The majority of previous research on the effects of MSCs 
has been executed in murine models or by observing M2-type 
switch using polarized monocytes. Especially, the effect of MSCs 
or MSC-EVs on the properties of mature Mregs has not been 
addressed before. In this study, we focused on interplay in resolu-
tion and investigated the effects of human MSC coculture and 
MSC-EVs on the human Mreg population. The levels of cytokines 
and LMs were analyzed from conditioned media. In addition, we 
evaluated phagocytic ability and the alterations of phenotype 
marker expression of the Mreg population. Our novel findings 
indicate that both MSC coculture and MSC-EVs enhance the 
anti-inflammatory phenotype of Mregs by downregulating the 
production of IL-23 and IL-22. We identified several LMs and 
pathway markers from human Mreg-, MSC-, and EV-conditioned 
media. The results manifest that MSC-EVs may also mediate the 
discovered changes in cytokine levels via PGE2, and thus promote 
the resolution of inflammation.
MaTerials anD MeThODs
Msc culture
Human bone marrow-derived MSCs from two donors (35, 36) 
at passage 4 were thawed, and 1,200 cells/cm2 were plated on 
10 cm plates (Nunclon™ Delta Surface, Thermo Fisher Scientific) 
in 10 ml α-MEM (Gibco) supplemented with 10% fetal bovine 
serum (FBS) (Gibco), 20 mM HEPES (Gibco), 100 U/ml penicil-
lin, and 100  µg/ml streptomycin (Gibco). The cells were incu-
bated at 37°C, 5% CO2 for 5 days, and the medium was renewed 
after 24 h. The cells were washed with 5 ml warm endotoxin-free 
phosphate-buffered saline (PBS) with or without (w/o) Ca2+/
Mg2+ (Gibco DPBS CTS™) and detached with 1.5 ml TrypLE™ 
Express (Gibco). The detachment process was stopped with 
5 ml warm 10% FBS (Sigma-Aldrich) in RPMI Medium 1640, 
GlutaMAX™ Supplement (Gibco), and the cells were centrifuged 
at 500 g for 5 min. The pellet was suspended with 10% FBS in 
RPMI Medium 1640, GlutaMAX™ Supplement, and cells were 
counted with NucleoCounter® NC-100™ (ChemoMetec).
Msc-Derived extracellular Vesicle 
extraction
Human bone marrow-derived MSC from two donors (35, 36) 
at passage 4 were thawed, and 1,200 cells/cm2 were plated on 
two 15 cm plates in 30 ml α-MEM supplemented with 10% FBS, 
20 mM HEPES, 100 U/ml penicillin, and 100 µg/ml streptomy-
cin. The cells were incubated at 37°C, 5% CO2 for 6 days, and the 
medium was renewed after 24 h. The cells were detached with 
TrypLE™ Express, and 1,300 cells/cm2 were plated on two-
chamber type of Corning® CellSTACK® cell culture chambers 
(Sigma-Aldrich) in 250 ml medium. The chamber cultivation 
continued at 37°C, 5% CO2 for 3  days, and the medium was 
renewed after 24  h. Before starvation, the cells were washed 
three times with 100  ml PBS and once with 75  ml α-MEM. 
During starvation, the cells were incubated in 200 ml serum-
free starvation medium α-MEM at 37°C, 5% CO2 for 2  days. 
The media were collected and centrifuged at 2,000 g for 10 min 
to remove cell debris. The supernatant was ultracentrifuged 
with Optima™ MAX-XP Ultracentrifuge (Beckman Coulter) 
at 100,000  g 1.5  h +4°C with MLA-50 rotor (k-factor =  92, 
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Beckman Coulter), and the pelleted EVs were combined. For 
the second EV collection, the cell starvation was continued in 
200 ml α-MEM at 37°C, 5% CO2 for 2 days followed by replica-
tion of EV centrifugation steps.
Macrophage Polarization assay
The schematic overview of macrophage polarization assay is pre-
sented in Figure S1 in Supplementary Material, and the detailed 
method is described in Supplementary Methods in Supplemen-
tary Material.
Briefly, human peripheral blood mononuclear cells (PBMC) 
were extracted from buffy coats using Ficoll-Pague™ Plus (GE 
Healthcare Life Sciences) density gradient centrifugation at day 
0. Monocyte selection was performed by plating 2 × 106 PBMC/
well in Nunclon™ Delta Surface 24-well plates (Thermo Fisher 
Scientific) in RPMI Medium 1640 (Gibco), incubating at 37°C, 
5% CO2 for 2 h. The attached monocytes were incubated at 37°C, 
5% CO2 for 6 days in the following Polarization Media: 5 ng/ml 
M-colony stimulating factor (CSF) (PromoCell), 10% FBS (Sigma-
Aldrich) in RPMI Medium 1640, GlutaMAX™ Supplement for 
Mreg polarization; 50 ng/ml GM-CSF (PromoCell), 10% FBS in 
RPMI Medium 1640, GlutaMAX™ Supplement for M1 polariza-
tion; and 50 ng/ml M-CSF, 10% FBS in RPMI Medium 1640, 
GlutaMAX™ Supplement for M2 polarization.
At day 6, the media were replaced with the following 
Acti vation Media: 25  ng/ml interferon (IFN)-γ, 10  ng/ml 
lipopolysaccharide (LPS), 5  ng/ml M-CSF, 10% FBS in RPMI 
Medium 1640, GlutaMAX™ Supplement for Mreg polarization; 
50 ng/ml IFN-γ, 10 ng/ml LPS, 50 ng/ml GM-CSF, 10% FBS in 
RPMI Medium 1640, GlutaMAX™ Supplement for M1 polariza-
tion; and 20  ng/ml IL-4, 50 ng/ml M-CSF, 10% FBS in RPMI 
Medium 1640, GlutaMAX™ Supplement for M2 polarization. 
The added media volume was 500 µl in treatment wells and 600 µl 
in control wells. The incubation was continued at 37°C, 5% CO2.
At day 7, 20,000 MSCs in 100  µl Mreg/M1/M2 Activation 
media were added into representative treatment wells. The final 
media volume was 600 μl/well, and the cells were incubated at 
37°C, 5% CO2 for 3 days. Alternatively, in MSC-EV supplementa-
tion experiments, at day 7, isolated EVs from one two-chamber 
were suspended in Mreg Activation Media, and 50 µl was added 
into 30 representative treatment wells. The supplementation was 
repeated at day 9, and isolated EVs in 50 µl representative Mreg 
Activation Media were added into each well. The final media 
volume was 600 μl/well, and the cells were incubated at 37°C, 5% 
CO2 for 3 days.
At day 10, media samples were collected from each well and 
centrifuged at 300  g for 15  min at RT. The supernatants were 
snap frozen on dry ice and stored at −70°C. Cell samples for 
flow cytometry analysis were detached with 0.5  ml/well cold 
Macrophage Detachment Solution DFX (PromoCell).
Phagocytosis assay
The phagocytic ability of Mregs was determined at day 10 of 
Macrophage assay using a Phagocytosis Assay Kit (IgG FITC) 
(Cayman Chemicals) according to the manufacturer’s instruc-
tions. Briefly, latex beads coated with FITC-labeled rabbit IgG 
were added in 1:300 dilution in 200  µl Polarization media II 
on Mregs and incubated at +37°C, 5% CO2 for 4 h in Cell-IQ® 
automated cell culture and analysis system (CM Technologies 
Oy). After incubation, the cells were washed with 1 ml warm PBS 
and detached with 0.5  ml/well cold Macrophage Detachment 
Solution DFX. The cells were suspended up to 15  ml PBS and 
centrifuged at 350 g for 10 min. To quench cell-bound external 
fluorescence, the pellets were suspended with 45 µl Phagocytosis 
Kit Assay Buffer (Cayman Chemicals) and 5 µl 10× Trypan Blue 
Quenching Solution (Cayman Chemicals) was added followed 
by 1–2 min incubation at RT. The cells were washed with 2 ml 
Phagocytosis Kit Assay Buffer, centrifuged at 350 g for 10 min, 
and suspended in 50 µl 0.3% bovine serum albumin, 2 mM EDTA 
in PBS, pH 7.2.
Macrophage Phenotyping Using Flow 
cytometry analysis
The antibody staining was performed with PE-CD80 (clone 
2D10.4, mouse IgG1 k, eBioscience), PE-Cy7-CD86 [clone 2331 
(FUN-1), mouse IgG1 k, BD Biosciences], BV421-CD163 (clone 
GHI/61, mouse IgG1 k, BD Biosciences), and APC-CD206 
(clone 19.2, mouse IgG1 k, BD Biosciences) according to the 
manufacturers’ instructions. Respectively, conjugated isotype 
control antibodies were used as negative control for background 
staining. Macrophages were suspended in 50 µl staining buffer 
(0.3% bovine serum albumin, 2 mM EDTA in PBS, pH 7.2) and 
incubated with 2.5 µg of Human BD Fc Block™ (BD Biosciences) 
for 10 min at RT. The pre-mixed fluorescent antibody cocktail was 
added, and the cells were incubated on ice in darkness for 30 min. 
After staining, the cells were washed with 2 ml staining buffer, 
pelleted by centrifuging at 350 g for 10 min, and suspended in 
100 µl staining buffer.
Cell data were acquired with BD FACSAria IIU (BD 
Biosciences) flow cytometer using FACSDiva™ version 8.0.1 
software (BD Biosciences) and analyzed with FlowJo® version 
10.0.7 software (FlowJo, LLC). Macrophages were gated based 
on forward (FSC) and side (SSC) scatter patterns. Doublets and 
aggregates were excluded using FSC area versus FSC height. 
The fluorescence positive cells were gated based on isotype 
controls and populations. The results are represented as median 
fluorescence intensity (FRI) and frequency of positive cells. 
The representative gating strategy is presented in Figure S2 in 
Supplementary Material.
cytokine Measurements
The cell culture media from Macrophage polarization assay 
was analyzed for 18 cytokines using human Th1/Th2/Th9/
Th17/Th22/Treg 18 Plex ProcartaPlex Immunoassay (eBiosci-
ence) according to the manufacturer’s instructions. The media 
samples were thawed on ice, and three technical replicates from 
each experiment were pooled together. Briefly, 50 µl of samples 
and standards was incubated with magnetic beads followed by 
washing steps and the detection antibody mixture. After addition 
of streptavidin-PE, the signal data were acquired on Luminex® 
100 system (Luminex). The data were analyzed with ProcartaPlex 
Analyst 1.0 Software (Thermo Fisher Scientific). Measures 
within the cytokine-specific detection range were included in the 
Table 1 | Characteristics of Mregs and other macrophage subtypes.
Protein M1 (n = 3–4) M2 (n = 3–4) Mreg (n = 13)
Median Fri (iQr) p-Valuea
CD80 576 (158) 484 (53) 468 (196) 0.060
CD86 11,085 (6,604) 8,262 (6,803) 3,950 (4,845) 0.039
CD163 702 (451) 1,409 (1,220) 1,076 (679) 0.047
CD206 937 (423) 2,476 (1,941) 287 (74) <0.001
Median frequency of positive cells (%) p-Valuea
CD80 15 (10) 8 (34) 40 (42) 0.011
CD86 97 (18) 87 (34) 67 (33) 0.012
CD163 1 (0) 12 (13) 25 (27) <0.001
CD206 58 (26) 77 (22) 14 (11) <0.001
FRI, fluorescence intensity; IQR, interquartile range; M1, classically activated “host 
defense” macrophage; M2, alternatively activated “wound-healing” macrophage; Mreg, 
regulatory macrophage.
aThe significance in variation between M1, M2, and Mreg was analyzed using the 
Kruskal–Wallis test.
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analysis, except the tumor necrosis factor (TNF)-α analysis, in 
which, for certain M1 samples, the upper limit of the detection 
range was used.
identification of lMs and  
Pathway Markers
The levels of LMs and pathway markers were determined using 
liquid chromatography–tandem mass spectrometry (LC–MS/MS). 
The media samples were analyzed for LMs thromboxane (Tx)B2, 
PGE2, PGD2, 15-deoxy-Δ12,14-PGJ2, leukotriene B4, LXA4, RvD1, 
RvD2, RvD3, maresin 1, 10S,17S-dihydroxydocosahexaenoic 
acid (diHDHA) (also known as protectin DX), and monohydroxy 
pathway markers 15-hydroxyeicosatetraenoic acid (HETE), 
18-hydroxyeicosapentaenoic acid (HEPE), 17-HDHA, and 
14S-HDHA.
The cell culture samples were thawed on ice, and three volumes 
of methanol containing 500  pg of internal standards d4-PGE2  
and d5-RvD2 were added to the sample. Then, samples were 
incubated for 45  min at −20°C for protein precipitation. The 
samples were centrifuged at 700 g for 15 min, and the supernatant 
was filtered using Captiva ND Lipids filtration device (Agilent 
Technologies), which trapped phospholipids but allowed LMs to 
pass through. The eluate was then concentrated to 75 µl, and 5 µl 
was injected to the LC–MS/MS system. The LMs and pathway 
markers were analyzed by using 6490 Triple Quadrupole LC/MS 
equipment with Agilent Jet Stream and iFunnel Technology cou-
pled with 1290 Infinity LC (Agilent Technologies). For chromato-
graphic separation, a ZorBAX Eclipse Plus C18 RRHD analytical 
column (2.1 mm × 50 mm, 1.8 µm, Agilent Technologies) was 
used. The LC–MS/MS method employed multiple reaction moni-
toring (MRM) detection for each LM (Table S1 in Supplementary 
Material) with the LC phases and optimized source parameters 
described by Le Faouder et al. (37).
Samples were analyzed as triplicates. The criteria used to 
identify a peak were as follows: (1) retention time of the peak 
was matched with the standard, (2) a peak eluted at the correct 
retention time in both Quantifier and Qualifier MRM scans of a 
single mediator, and (3) all of the triplicate sample runs contained 
a peak. The data were analyzed with MassHunter Quantitative 
Analysis software version 6.00 (Agilent Technologies) using the 
Quantifier MRM for quantitative analysis (Q3 quant, Table 3). 
Concentrations were normalized against the respective internal 
standards (Table S1 in Supplementary Material), and the detec-
tion limit was 0.2 ng/ml.
statistical analyses
Statistical analyses were performed with GraphPad PRISM®  
version 7.02 (GraphPad Software). Due to a relatively low number 
of biological replicates and non-normal distribution of variables, 
non-parametric statistical methods were applied. The values 
of cell culture media cytokines were log10-transformed. The 
variation of cytokines and flow cytometry results between M1-, 
M2-, and Mreg-conditioned media groups was analyzed by the 
Kruskal–Wallis test, and pairwise analyses were executed using 
the Mann–Whitney U tests. When assessing the variation of the 
levels of cytokines and LMs in Mreg-conditioned media w/o MSC 
coculture or MSC-EVs, the Wilcoxon matched-pairs signed-rank 
test was used. The results are expressed as median with interquar-
tile ranges. p-Values < 0.05 were considered significant.
ethical Permits
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resUlTs
characteristics of Mregs and Other 
Macrophage subtypes
Phenotypes of Mreg, M1, and M2 were assessed by the flow 
cytometry analysis of T cell activation co-stimulatory molecules 
CD80 and CD86, scavenger receptor CD163, and mannose 
receptor CD206, and the results are presented in Table  1. 
The observed Mreg phenotype was CD80low/intermediate, CD86+, 
CD163low, and CD206low. Approximately 40% of Mregs were 
positive for CD80, 70% for CD86, 25% for CD163, and 14% for 
CD206 expression. All the median FRIs and the frequencies of 
positive cells significantly differed between the studied mac-
rophage subtypes, except the median FRI of CD80 (Table  1). 
When analyzing the subtypes pairwise (Figure 1), we observed 
that the median FRI of CD80 was higher among M1 than among 
Mreg (p = 0.027). All macrophage subtypes were highly posi-
tive for CD86. Both the median FRI of CD86 (p = 0.032) and 
frequency of CD86 positive cells (p = 0.006) were higher among 
M1 than Mreg.
The observed phenotype differences were more prominent 
between Mreg and M1 than between Mreg and M2. The major 
exception was CD206; when analyzed pairwise, both median 
FRI (p = 0.003) and frequency of CD206+ cells (p < 0.001) were 
higher among M2 than Mreg.
FigUre 1 | Phenotypes of M1, M2, and Mreg subtypes. The antibody staining was performed with PE-CD80, PE-Cy7-CD86, BV421-CD163, and APC-CD206 
according to the manufacturers’ instructions. The median fluorescence intensities (left panel) and frequencies of positive cells (right panel) were determined with flow 
cytometry analysis. The significance in pairwise variation between M1 and Mreg, and M2 and Mreg was analyzed using the Mann–Whitney U test. The results are 
presented as median with interquartile range. The number of biological replicates varied from 3 to 13. Abbreviations: FRI, fluorescence intensity; M1, classically 
activated “host defense” macrophage; M2, alternatively activated “wound-healing” macrophage; Mreg, regulatory macrophage.
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The results of cytokines in Mreg-, M1-, and M2-conditioned 
media are presented in Figure 2. The levels of IL-1β, IL-2, IL-5, 
TNF-α, IL-10, IL-22, and IL-23 significantly varied between the 
macrophage-conditioned media groups. When compared pair-
wise, compared with M1-conditioned media, the levels of IL-1β 
(p = 0.003), IL-2 (p = 0.010), IL-5 (p = 0.002), TNF-α (p = 0.003), 
FigUre 2 | Level of cytokines in Mreg-, M1-, and M2-conditioned media. The media were analyzed for 18 cytokines, and measures within the cytokine-specific 
detection range were included in the analysis. The values of cell culture media cytokines were log10-transformed. The significance in pairwise variation between M1 
and Mreg, and M2 and Mreg was analyzed using the Mann–Whitney U test, and the results are expressed as median with interquartile range. The number of 
biological replicates varies from 3 (for M1 and M2) to 15 for Mreg. Abbreviations: IL, interleukin; M1, classically activated “host defense” macrophage; M2, 
alternatively activated “wound-healing” macrophage; Mreg, regulatory macrophage.
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IL-22 (p = 0.005), and IL-23 (p = 0.003) in Mreg-conditioned media 
were significantly lower. By contrast, the level of IL-10 was higher 
in Mreg-conditioned media than in M1- and M2-conditioned 
media (p = 0.003 for both comparisons). In addition, the levels 
of IL-22 and IL-23 were higher in Mreg-conditioned media than 
in M2-conditioned media (p = 0.017 and p = 0.016, respectively).
Table 2 | Effect of MSC coculture or MSC-EVs on Mreg phenotype.
Protein Mregs w/o Msc coculture Mregs w/o Msc-eVs
Mreg (n = 11) Mreg + Msc (n = 11) Mreg (n = 8) Mreg + Msc-eV (n = 8)
Median Fri (iQr) p-Valuea Median Fri (iQr) p-Valueb
CD80 417 (170) 443 (151) 0.365 524 (256) 548 (276) 0.188
CD86 3,950 (4,845) 2,998 (6,480) 0.414 2,601 (1,820) 3,593 (2,665) 0.109
CD163 1,076 (679) 730 (529) 0.003 1,012 (560) 967 (468) 0.016
CD206 287 (74) 245 (154) 0.060 264 (74) 245 (45) 0.031
Median frequency of positive cells (%) p-Valuea Median frequency of positive cells (%) p-Valueb
CD80 40 (36) 31 (44) 0.024 57 (30) 58 (36) 0.547
CD86 67 (33) 42 (39) 0.376 80 (21) 87 (13) 0.016
CD163 25 (27) 7 (12) 0.002 19 (15) 9 (12) 0.016
CD206 14 (11) 3 (3) 0.008 9 (8) 9 (2) 0.078
EV, extracellular vesicle; IQR, interquartile range; Mreg, regulatory macrophage; MSC, mesenchymal stromal cell; FRI, fluorescence intensity; MSC-EVs, MSC-derived extracellular 
vesicles; w/o, with or without.
aThe statistical significance of variation between Mregs and Mregs with MSC coculture was determined using the Wilcoxon matched-pairs signed-rank test.
bThe statistical significance of variation between Mregs and Mregs with MSC-EVs was determined using the Wilcoxon matched-pairs signed-rank test.
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effect of Msc coculture or Msc-eVs on 
Mreg Phenotype
The effects of MSC coculture or MSC-EVs on Mreg CD80, CD86, 
CD163, and CD206 phenotype were assessed by flow cytometry 
analysis and the representative raw data overlays are presented in 
Figures S3 and S5 in Supplementary Material, respectively. The 
pairwise analyses are depicted in Table 2 and Figures S4 and S6 
in Supplementary Material. The MSC coculture did not affect 
the median FRI of CD80 in Mregs; however, the frequency of 
CD80+ Mregs was lower in the coculture than in Mreg culture 
alone (p = 0.024). We observed no significant change in CD86 
expression and frequency among Mregs. The median FRI of 
scavenger receptor CD163 expression significantly decreased in 
Mregs when cocultured with MSC (p = 0.003). In addition, the 
frequency of CD163+ Mregs was lower in the coculture than in 
Mreg culture alone (p =  0.002). The same trend was observed 
in mannose receptor CD206 expression and the frequency of 
positive Mregs, even though only the reduction in frequency 
was significant (p = 0.060 for CD206 median FRI; p = 0.008 for 
frequency of CD206+ Mregs).
In concordance with the MSC coculture results, MSC-EVs 
decreased the median FRI of CD163 (p = 0.016), and compared 
with Mregs cultured without EVs, reduced the frequency of 
CD163+ Mregs (p = 0.016) (Table 2; Figure S6 in Supplementary 
Material). Again, the same trend was observed in CD206 expres-
sion and frequency of positive Mregs, even though only the reduc-
tion of median FRI of CD206 reached significance (p = 0.031 for 
CD206 median FRI; p = 0.078 for frequency of CD206+ Mregs).
effect of Msc coculture and Msc-eVs on 
the cytokine levels of Mreg-conditioned 
Media
The cytokine levels were measured from Mreg-conditioned 
media without MSC coculture, and the results are presented in 
Figure 3. The levels of IL-10, IL-22, and IL-23 were significantly 
lower in Mreg-conditioned media with MSC coculture than 
without it (p =  0.003, p <  0.001, and p <  0.001, respectively). 
In addition, there was a positive trend toward decreased level of 
TNF-α after MSC coculture, even though the result did not reach 
significance (p = 0.064). This effect was more prominent among 
M1 subtype where the TNF-α production was more abundant 
(data not shown).
The cytokine levels were measured from Mreg-conditioned 
media w/o MSC-EVs and the results are presented in Figure 4. 
The levels of IL-22 and IL-23 were significantly lower in Mreg-
conditioned media with MSC coculture than without it (p = 0.008 
and p = 0.031, respectively).
effect of Msc coculture and Msc-eVs  
on the lMs and Pathway Markers of  
Mreg-conditioned Media
The levels of LMs and pathway markers were determined using 
LC–MS/MS, and identification of 7 out of the 15 metabolites 
addressed was successful. Table 3 displays the results for Mreg-
conditioned media w/o MSC coculture or MSC-EVs. The levels 
of arachidonic acid-derived PGE2 (p  =  0.002) and 15-HETE 
(p  =  0.020), and docosahexaenoic acid-derived 17-HDHA 
(p  =  0.009) were higher in Mreg-conditioned media with 
MSC coculture than in Mreg culture alone. When treated with 
MSC-EVs, compared with non-treated Mreg culture, the Mreg-
conditioned media showed a significant increase in the level of 
PGE2 (p = 0.031).
TxB2, PGE2, 15-HETE, 18-HEPE, 17-HDHA, and 14S-HDHA 
were also detected both from MSC-conditioned media and MSC-
EVs (Figure S7 in Supplementary Material).
effect of Msc coculture on the 
Phagocytic ability of Mreg
The phagocytic ability of Mregs was assessed using latex beads 
coated with FITC-labeled rabbit IgG. It was noted that mannose 
receptor CD206 expression of Mregs was highly upregulated 
by the addition of the immune complex in all experimental 
conditions, and after 4-h incubation, the median frequencies 
of CD206+ Mregs were >90% (data not shown). However, 
FigUre 3 | Effect of MSC coculture on the level of cytokines in Mreg-conditioned media. The media were analyzed for 18 cytokines and measures within the 
cytokine-specific detection range were included in the analysis. The values of cell culture media cytokines were log10-transformed. The variation of cytokines 
between Mreg-conditioned media with and without MSC coculture was analyzed by the Wilcoxon matched-pairs signed-rank test. The number of biological 
replicates varied from 9 to 12. Abbreviations: IL, interleukin; Mreg, regulatory macrophage; MSC, mesenchymal stromal cell.
8
Hyvärinen et al. MSC/MSC-EVs proresolving Effects on Mregs
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 771
there were neither significant differences in median FRI of 
FITC-IgG (p =  1.000) nor in frequency of FITC-IgG+ Mreg 
cells (p =  0.313) between Mregs culture alone and with MSC 
coculture (Figure 5).
DiscUssiOn
Active dampening of the inflammatory response is a key phe-
nomenon in the restoration of tissue homeostasis after infection 
or tissue damage. Resolution-phase macrophages orchestrate 
anti-inflammatory actions by secreting various factors, including 
IL-10 and SPMs (7). In this study, we investigated the effects of 
immunomodulative human bone marrow-derived MSCs and 
MSC-EVs on human Mregs. We observed that both MSC cocul-
ture and MSC-EVs enhanced the anti-inflammatory phenotype 
of Mreg by downregulating the production of IL-23 and IL-22. 
Several LMs and pathway markers were identified from Mreg-, 
MSC-, and EV-conditioned media. Interestingly, our results 
indicate that MSC-EVs may also mediate the discovered changes 
in cytokine levels via PGE2, and thus promote the resolution of 
inflammation.
Macrophage polarization and activation status strongly 
depend on the microenvironmental stimuli. Currently, the 
nomenclature system in the research field is heterogeneous and 
further confusion may arise from the fact that many murine 
markers fail to translate to human macrophages (4, 5). In the 
literature, “regulatory,” “Mreg,” or “immunosuppressive” macro-
phages comprise populations with a spectrum of characteristics 
evoked by different experimental conditions (6, 10). Common 
features include high IL-10 and TGF-β production. Mregs 
FigUre 4 | Effect of MSC-derived extracellular vesicles on the level of cytokines in Mreg-conditioned media. The media were analyzed for 18 cytokines, and 
measures within the cytokine-specific detection range were included in the analysis. The values of cell culture media cytokines were log10-transformed. The 
variation of cytokines between Mreg-conditioned media with and without MSC-EVs was analyzed by the Wilcoxon matched-pairs signed-rank test. The number of 
biological replicates is 8. Abbreviations: EV, extracellular vesicle; IL, interleukin; Mreg, regulatory macrophage; MSC, mesenchymal stromal cell; MSC-EVs, 
MSC-derived extracellular vesicles.
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are also potent antigen-presenting cells and express co- 
stimulatory molecules needed for T and B cell activation (38). In 
our study, we characterized the phenotype of human Mregs and 
compared it with those of the conventionally generated M1 and 
M2 populations. In concordance with the previous Mreg studies, 
the Mregs generated in our experiments produced substantially 
higher levels of IL-10 than M1 and M2 populations (10, 11). 
Despite the activation by M1-stimulus-like combination of 
IFN-γ and LPS, the phenotype and cytokine profile of Mregs 
resembled more M2 than M1. The levels of pro-inflammatory 
cytokines, such as TNF-α and IL-23, were markedly lower in 
Mreg-conditioned media than in M1-conditioned media, but 
higher that in M2-conditioned media. As expected, the vari-
ance in biological replicates was rather high due to differences 
in PBMC donors. However, the observed Mreg phenotype 
CD80low/intermediate, CD86+, CD163low, and CD206low resembled 
previous reports for the shared markers (6, 13).
It has been reported that MSCs modify the differen-
tiation of monocyte and macrophage populations toward anti- 
inflammatory or M2 phenotype, by, e.g., increasing IL-10 pro-
duction, the expression of scavenger receptors, and phagocytic 
ability (23–26, 39, 40). However, the majority of the work has 
been done either with mouse models, cell lines, or in conditions 
where macrophages are not pre-polarized. Therefore, the previ-
ous observations are not directly applicable to our findings due 
to the different phenotype of Mregs. We are the first to show 
the effect of MSCs and MSC-EVs on fully differentiated human 
Mregs in the presence of activation medium (LPS and IFN-γ). 
FigUre 5 | Effect of MSC coculture on the phagocytic ability of Mreg. The phagocytic ability of Mregs was assessed using latex beads coated with FITC-labeled 
rabbit IgG. The median FRI (left panel) and frequencies of positive cells (right panel) were determined with flow cytometry analysis. The variations between Mreg with 
and without MSC coculture were analyzed by the Wilcoxon matched-pairs signed-rank test. The number of biological replicates is 5. Abbreviations: FRI, 
fluorescence intensity; IgG, immunoglobulin G; Mreg, regulatory macrophage; MSC, mesenchymal stromal cell.
Table 3 | Levels of lipid mediators (LMs).
lM Tandem mass spectrometry Mreg-conditioned media w/o Msc coculture Mreg-conditioned media w/o Msc-eVs
Mass/charge Median (iQr)  
(ng/ml)a
Median (iQr) (ng/ml)b
Q1 Q3 (quant) Q3 (qual) Mreg (n = 12) Mreg + Msc 
(n = 12)
p-Valueb Mreg (n = 8) Mreg + Msc-eV 
(n = 8)
p-Valuec
arachidonic acid-derived
TxB2 369 169 195 15.5 (13.8) 18.4 (11.2) 1.000 19.6 (12.8) 12.1 (13.2) 0.547
PGE2 351 271 189 0.3 (0.9) 4.2 (2.8) 0.002  0.0 (0.6) 0.6 (0.9) 0.031
PGD2 351 189 233 0.0 (0.0) 0.0 (0.2) 0.250 ND ND ND
15-Deoxy-Δ12,14-PGJ2 315 271 203 ND ND ND ND ND ND
LTB4 335 195 59 ND ND ND ND ND ND
LXA4 351 115 217 ND ND ND ND ND ND
15-HETE 319 219 301 0.5 (1.0) 0.8 (1.0) 0.020 0.6 (0.1) 0.8 (0.8) 0.313
eicosapentaenoic acid-derived
18-HEPE 317 215 259 0.4 (0.4) 0.4 (0.1) 0.193 0.5 (0.3) 0.4 (0.3) 0.148
Docosahexaenoic acid-derived
RvD1 375 215 233 ND ND ND ND ND ND
RvD2 375 215 175 ND ND ND ND ND ND
RvD3 375 147 137 ND ND ND ND ND ND
10S,17S-diHDHA 359 153 206 ND ND ND ND ND ND
MaR1 359 177 250 ND ND ND ND ND ND
17-HDHA 343 245 201 0.7 (1.2) 1.1 (1.6) 0.009 1.0 (0.5) 0.9 (0.7) 0.945
14S-HDHA 343 205 161 0.4 (0.4) 0.4 (0.7) 0.359 0.3 (0.2) 0.4 (0.6) 0.078
diHDHA, dihydroxydocosahexaenoic acid; EV, extracellular vesicle; HDHA, hydroxydocosahexaenoic acid; HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic 
acid; IQR, interquartile range; LT, leukotriene; LX, lipoxin; MaR, maresin; Mreg, regulatory macrophage; MSC, mesenchymal stromal cell; ND, not detected; PG, prostaglandin; Qual, 
qualifier; Quant, quantifier; Rv, resolvin; Tx, thromboxane; w/o, with or without.
aThe LMs were identified using liquid chromatography–tandem mass spectrometry method with detection limit <0.2 ng/ml.
bThe statistical significance of variation between Mreg-conditioned media and Mreg-conditioned media with MSC coculture was determined using the Wilcoxon matched-pairs 
signed-rank test.
cThe statistical significance of variation between Mreg-conditioned media and Mreg-conditioned media with MSC-derived EVs was determined using the Wilcoxon matched-pairs 
signed-rank test.
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MSCs have been shown to decrease TNF-α secretion from mac-
rophages (39). In Mreg population, we observed a tendency for 
decreasing TNF-α. The reduction was much more prominent in 
the M1 population (data not shown) that produced this cytokine 
at a very high level. Furthermore, in contrast to the findings in 
M1/M2 axis, we detected that MSC coculture actually decreased 
the very high level of IL-10 in the conditioned media.
Both MSC coculture and MSC-EVs reduced the expression 
of CD163 and CD206 in Mregs, which differs from the previous 
M1/M2 axis results showing increased expression of M2 markers 
CD163 and CD206 (25, 39, 40). This observation is in accordance 
with the finding that MSCs did not enhance the FcγR-mediated 
IgG-binding phagocytosis of Mregs. Overall, phagocytosis 
is carried out by both opsonic (i.e., FcγR) and non-opsonic 
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(i.e., CD206) receptors, and the phagocytosis ability, especially 
of Mregs, could be reasonably investigated using apoptotic 
neutrophils, which are highly abundant at the resolution phase 
(7). Altogether, the differences in the MSC-derived effects reflect 
the nature of diverse macrophage populations, the variation in 
species, and other experimental conditions. Most likely, the role 
of Mreg in vivo is not primarily conventional phagocytosis, but 
more related to efferocytosis and immune regulation.
Our novel results indicate that both MSC coculture and MSC-
EVs are able to induce reduction in the levels of IL-23 and IL-22 
and thereby enhance the anti-inflammatory characteristics of 
Mregs. IL-23 is a pro-inflammatory cytokine that induces and 
maintains the Th17 effector T cell population and pathogenicity, 
and many chronic immune-mediated disorders, such as pso-
riasis, arthritis, and Crohn’s disease, are strongly associated with 
IL-23 dysregulation (41–44). On the other hand, IL-22 is a major 
secretory product of Th17, and the function of IL-22 has been 
reported to mediate IL-23-induced inflammation and crosstalk 
between tissue barrier cells and the cells of the immune system 
(45). Thus, reduction of both IL-23 and IL-22 could decrease the 
induction of highly pathogenic Th17 cells and thus exacerbation 
of inflammation (46). Intriguingly, it has been recently reported 
that Th17  cells contribute to the resolution of inflammation 
by differentiating into T  regulatory type 1 cells (47). We can 
therefore hypothesize that MSC coculture and MSC-EVs treated 
Mreg populations may promote resolution via reduction of Th17 
pathogenicity or Th17 conversion. The hypothesis is supported 
by findings by Chiossone et  al. (25), who reported induction 
of CD25highFoxp3+ regulatory T  cells by MSC-educated mac-
rophages and by Melief et al. (48) presenting that induction of 
regulatory T cells by MSC involves skewing monocytes toward 
M2-type macrophages.
Specialized proresolving mediators are synthetized from n-6 
and n-3 fatty acids such as arachidonic acid, eicosapentaenoic acid, 
and docosahexaenoic acid. The biosynthetic pathways of SPMs 
include multiple intermediates, which may also serve as pathway 
markers (49). We identified TxB2, PGE2, 15-HETE, 18-HEPE, 
17-HDHA, and 14S-HDHA from the Mreg-conditioned media 
with both MSC coculture and MSC-EVs. These molecules belong 
to the reported LM profiles produced by human macrophages 
(16). We could not detect any proresolving end products, the 
levels of which likely remained under the detection limit of our 
LC–MS/MS system. Although a well-known macrophage-derived 
SPM, maresin 1, was not detected with the current method, a 
maresin pathway marker, 14S-HDHA, was identified. Generally, 
monohydroxy pathway markers are more stable than SPM end 
products.
We observed that MSCs and, for the first time, MSC-EVs 
increased the PGE2 production in the Mreg coculture. Conven-
tionally, the PGE2 has been regarded as a pro-inflammatory 
molecule participating in the initiation of inflammation. How-
ever, PGE2 also possesses immunosuppressive properties (50, 51) 
and is considered one of the most potent immunosuppressive 
mechanisms of MSCs (21), shown also in the context of mac-
rophage polarization by MSCs (23–25). The dual function of 
PGE2 might arise from the differing activities of PGE2 receptors 
(EPs). Poloso et  al. recently reported that PGE2 regulates the 
IL-23 release in human monocyte-derived dendritic cells and 
that at low PGE2 concentrations the high-affinity EP4 increased 
IL-23 production (52). Another receptor, EP2 has been sug-
gested to respond to high PGE2 amounts by downregulating the 
IL-23 release (52, 53). The mechanism via the EP2 may partly 
explain the observations of high PGE2 and decreased IL-23 in 
our study. The fact that MSC-EVs are also able to induce the 
production of PGE2 from responder cells represents an interest-
ing novel mechanism of action supported by the findings of Liu 
et al. (54).
Prostaglandin E2 has been shown to induce LM class switch-
ing in neutrophils. Modulation of 5- and 15-LOX expressions 
leads to the inhibition of pro-inflammatory leukotriene B4 and 
increased production of proresolving LXA4 and its pathway 
marker 15S-HETE in neutrophils (14). In this study, the level 
of 15-HETE was increased in the coculture of Mreg and MSC, 
which may imply that the elevated concentration of PGE2 
acted as a cue for LM class switching. During the course of 
resolution, other SPMs, such as Rvs, protectins, and maresins, 
are produced (15). Interestingly, RvD1, RvD2, and RvE1 have 
been reported to reduce IL-23 production in asthma, microbial 
peritonitis, and allergic airway mouse models, respectively 
(55–57). These findings suggest a possible association between 
the PGE2-induced class switching and the observed reduced 
IL-23 production.
Human Mregs have been investigated in cell-based immuno-
suppressive therapy in early-phase clinical trials in renal transplan-
tations (6, 13, 58), and altogether, the need for the development 
of cell-based medicinal products is increasing. Modification of 
Mregs into enhanced tolerance-promoting phenotype is of inter-
est, and our results displaying the reduction of IL-23 and IL-22, 
support a potential role for combining therapeutic Mregs with 
MSC or MSC-EVs. The underlying mechanisms, including the 
MSC-EV-derived induction of PGE2 production and the possible 
conversion of Th17 into regulatory T cells, require further studies.
cOnclUsiOn
In this study, we demonstrate that human MSCs and MSC-EVs 
are capable of inducing proresolving changes in mature human 
Mregs. Both MSCs and MSC-EVs decrease the production of 
pro-inflammatory IL-23 and IL-22 while increasing immunosup-
pressive PGE2 production. Our findings suggest that MSCs and 
MSC-EVs may potentiate the proresolving phenotype of Mregs 
and supports the rationale of further studying the underly-
ing mechanisms. Priming of Mregs with MSC or MSC-EVs is 
a potential novel approach for promoting the efficacy of Mreg 
therapy.
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